Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold

Serina Therapeutics, Inc.

2025-Q3 EPS reported -$1.60 revenue$130,000

Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.
FDA placed IND for SER-252 on clinical hold due to excipient question; not related to active drug.
Secured up to $20M convertible note/warrant financing; first $5M drawn in September 2025.
ATM program raised $2.8M net; 474,712 shares issued at avg $6.00 per share.
Cash $8.6M as of Sept 30; R&D expenses rose to $3.6M from $2.4M year-over-year.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.